COMPASS Pathways (NASDAQ:CMPS) Posts Earnings Results, Misses Estimates By $0.01 EPS

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports.

COMPASS Pathways Trading Down 6.6 %

Shares of COMPASS Pathways stock traded down $0.26 during mid-day trading on Monday, hitting $3.67. The stock had a trading volume of 1,262,910 shares, compared to its average volume of 724,748. The firm has a 50-day moving average of $4.06 and a two-hundred day moving average of $5.21. COMPASS Pathways has a 12-month low of $3.17 and a 12-month high of $12.57. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market cap of $251.11 million, a P/E ratio of -1.67 and a beta of 2.28.

Wall Street Analyst Weigh In

A number of research firms have commented on CMPS. Canaccord Genuity Group cut their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday. Stifel Nicolaus began coverage on shares of COMPASS Pathways in a report on Thursday. They issued a "buy" rating and a $11.00 price objective for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, HC Wainwright cut their price objective on shares of COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $21.83.

Remove Ads

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.